Immix Biopharma, Inc.IMMXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank60
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P60
Within normal range
vs 2Y Ago
0x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
202429.28%
2023108.19%
20223216.11%
2021-49.01%
2020-57.45%
20190.00%